Ropinirole differs from bromocriptine in the following respect: A. It does not directly activate dopamine D2 receptors B. It produces milder gastrointestinal side effects C. In early cases of parkinsonism, it is less likely to need levodopa supplementation D. Both 'B' and 'C' are correct

Ropinirole differs from bromocriptine in the following
respect:
A. It does not directly activate dopamine D2
receptors
B. It produces milder gastrointestinal side
effects
C. In early cases of parkinsonism, it is less
likely to need levodopa supplementation
D. Both 'B' and 'C' are correct
by

1 Answer

Answer :

D. Both 'B' and 'C' are correct
by

Related questions

In the treatment of parkinsonism, bromocriptine differs from levodopa in the following respects except: A. It does not need conversion to an active metabolite B. It has a longer duration of action C. It activates dopamine D2 receptors, with little/antagonistic action on D1 receptors D. It does not produce behavioral/psychiatric side effect

Description : In the treatment of parkinsonism, bromocriptine differs from levodopa in the following respects except: A. It does not need conversion to an active metabolite B. It has a longer duration of ... with little/antagonistic action on D1 receptors D. It does not produce behavioral/psychiatric side effect

Last Answer : D. It does not produce behavioral/psychiatric side effects

Though bromocriptine acts directly on dopamine receptors, it is used in parkinsonism only as a supplement to levodopa because: A. It has low efficacy B. It produces marked dyskinesias C. Used alone, its effective doses produce intolerable side effects D. Its therapeutic effect takes long time to develop

Description : Though bromocriptine acts directly on dopamine receptors, it is used in parkinsonism only as a supplement to levodopa because: A. It has low efficacy B. It produces marked dyskinesias C. ... its effective doses produce intolerable side effects D. Its therapeutic effect takes long time to develop

Last Answer : C. Used alone, its effective doses produce intolerable side effect

The following is true about entacapone except: A. It acts by inhibiting degradation of dopamine in the brain B. If prolongs the therapeutic effect of levodopacarbidopa in parkinsonism C. It can accentuate levodopa induced dyskinesias D. It can cause diarrhoea as a side effec

Description : The following is true about entacapone except: A. It acts by inhibiting degradation of dopamine in the brain B. If prolongs the therapeutic effect of levodopacarbidopa in parkinsonism C. It can accentuate levodopa induced dyskinesias D. It can cause diarrhoea as a side effec

Last Answer : A. It acts by inhibiting degradation of dopamine in the brain

What is true of risperidone: A. It is an atypical neuroleptic which produces few extrapyramidal side effects B. It has combined dopamine D2 and 5-HT2 receptor blocking activity C. It does not cause hyperprolactinemia D. Both 'A' and 'B' are correct

Description : What is true of risperidone: A. It is an atypical neuroleptic which produces few extrapyramidal side effects B. It has combined dopamine D2 and 5-HT2 receptor blocking activity C. It does not cause hyperprolactinemia D. Both 'A' and 'B' are correct

Last Answer : D. Both 'A' and 'B' are correct

For majority of patients of parkinsonism the standard drug therapy is: A. Levodopa B. Levodopa + carbidopa C. Levodopa + trihexiphenidyl D. Bromocriptine

Description : For majority of patients of parkinsonism the standard drug therapy is: A. Levodopa B. Levodopa + carbidopa C. Levodopa + trihexiphenidyl D. Bromocriptine

Last Answer : B. Levodopa + carbidopa

The following drug is effective in chlorpromazine induced parkinsonism: A. Trihexyphenidyl B. Selegiline C. Bromocriptine D. Levodopa + carbidopa

Description : The following drug is effective in chlorpromazine induced parkinsonism: A. Trihexyphenidyl B. Selegiline C. Bromocriptine D. Levodopa + carbidopa

Last Answer : A. Trihexyphenidyl

The following drug combination should not be used in parkinsonism: A. Levodopa + anticholinergics B. Levodopa + amantadine C. Bromocriptine + levodopa D. Amantadine + anticholinergics

Description : The following drug combination should not be used in parkinsonism: A. Levodopa + anticholinergics B. Levodopa + amantadine C. Bromocriptine + levodopa D. Amantadine + anticholinergics

Last Answer : D. Amantadine + anticholinergics

The most effective drug in parkinsonism is: A. Bromocriptine B. Selegiline C. Levodopa + carbidopa D. Biperiden

Description : The most effective drug in parkinsonism is: A. Bromocriptine B. Selegiline C. Levodopa + carbidopa D. Biperiden

Last Answer : C. Levodopa + carbidopa

The primary action by which entacapone and tolcapone enhance the therapeutic effect of levodopa-carbidopa in parkinsonism is: A. Inhibition of levodopa methylation in the liver B. Inhibition of dopamine methylation in the brain C. Inhibition of oxidative deamination of dopamine in the brain D. Facilitation of active transport of levodopa across brain capillaries

Description : The primary action by which entacapone and tolcapone enhance the therapeutic effect of levodopa-carbidopa in parkinsonism is: A. Inhibition of levodopa methylation in the liver B. Inhibition of ... of dopamine in the brain D. Facilitation of active transport of levodopa across brain capillaries

Last Answer : A. Inhibition of levodopa methylation in the liver

The dopamine D2 receptor has the following feature: A. It is excitatory in nature B. It is negatively coupled to adenyl cyclase C. It is selectively blocked by bromocriptine D. It is not blocked by metoclopramide

Description : The dopamine D2 receptor has the following feature: A. It is excitatory in nature B. It is negatively coupled to adenyl cyclase C. It is selectively blocked by bromocriptine D. It is not blocked by metoclopramide

Last Answer : B. It is negatively coupled to adenyl cyclase

6.12 The most prominent action of bromocriptine is: A. Dopamine D2 agonism B. Dopamine D2 antagonism C. Dopamine D1 antagonism D. α adrenergic antagonism

Description : 6.12 The most prominent action of bromocriptine is: A. Dopamine D2 agonism B. Dopamine D2 antagonism C. Dopamine D1 antagonism D. α adrenergic antagonism

Last Answer : A. Dopamine D2 agonism

Cisapride enhances gastrointestinal motility by: A. Activating serotonin 5-HT4 receptor B. Activating muscarinic M3 receptor C. Blocking dopamine D2 receptor D. All of the above

Description : Cisapride enhances gastrointestinal motility by: A. Activating serotonin 5-HT4 receptor B. Activating muscarinic M3 receptor C. Blocking dopamine D2 receptor D. All of the above

Last Answer : A. Activating serotonin 5-HT4 receptor

Select the prokinetic-antiemetic drug which at relatively higher doses blocks both dopamine D2 as well as 5-HT3 receptors and enhances acetylcholine release from myenteric neurones: A. Cisapride B. Prochlorperazine C. Metoclopramide D. Domperidon

Description : Select the prokinetic-antiemetic drug which at relatively higher doses blocks both dopamine D2 as well as 5-HT3 receptors and enhances acetylcholine release from myenteric neurones: A. Cisapride B. Prochlorperazine C. Metoclopramide D. Domperidon

Last Answer : C. Metoclopramide

Blockade of both dopamine D2 and serotonin 5-HT2A/2C receptors is a distinctive feature of: A. Pimozide B. Haloperidol C. Ketanserin D. Clozapine

Description : Blockade of both dopamine D2 and serotonin 5-HT2A/2C receptors is a distinctive feature of: A. Pimozide B. Haloperidol C. Ketanserin D. Clozapine

Last Answer : D. Clozapine

Compared to other antipsychotic drugs, the distinctive feature of penfluridol is: A. Very long duration of action B. Weak dopamine D2 blocking activity C. Lack of extrapyramidal side effects D. Additional 5-HT2 receptor blocking activity

Description : Compared to other antipsychotic drugs, the distinctive feature of penfluridol is: A. Very long duration of action B. Weak dopamine D2 blocking activity C. Lack of extrapyramidal side effects D. Additional 5-HT2 receptor blocking activity

Last Answer : A. Very long duration of action

Entacapone differs from tolcapone in the following respect/respects: A. It is shorter acting B. It acts only by inhibiting peripheral metabolism of levodopa C. It is not hepatotoxic D. All of the above are correct

Description : Entacapone differs from tolcapone in the following respect/respects: A. It is shorter acting B. It acts only by inhibiting peripheral metabolism of levodopa C. It is not hepatotoxic D. All of the above are correct

Last Answer : D. All of the above are correct

Gynaecomastia can occur as a side effect of: A. Bromocriptine B. Cimetidine C. Famotidine D. Levodopa

Description : Gynaecomastia can occur as a side effect of: A. Bromocriptine B. Cimetidine C. Famotidine D. Levodopa

Last Answer : B. Cimetidine

Dobutamine differs from dopamine in that (a) It does not activate peripheral dopaminergic receptors (b) It does not activate adrenergic ß receptors (c) It causes pronounced tachycardia (d) It has good blood-brain barrier penetrability

Description : Dobutamine differs from dopamine in that (a) It does not activate peripheral dopaminergic receptors (b) It does not activate adrenergic ß receptors (c) It causes pronounced tachycardia (d) It has good blood-brain barrier penetrability

Last Answer : Ans: A

Dobutamine differs from dopamine in that: A. It does not activate peripheral dopaminergic receptors B. It does not activate adrenergic β receptors C. It causes pronounced tachycardia D. It has good blood-brain barrier penetrability

Description : Dobutamine differs from dopamine in that: A. It does not activate peripheral dopaminergic receptors B. It does not activate adrenergic β receptors C. It causes pronounced tachycardia D. It has good blood-brain barrier penetrability

Last Answer : A. It does not activate peripheral dopaminergic receptors

Dobutamine differs from dopamine in that: A. It does not activate peripheral dopaminergic receptors B. It does not activate adrenergic β receptors C. It causes pronounced tachycardia D. It has good blood-brain barrier penetrability

Description : Dobutamine differs from dopamine in that: A. It does not activate peripheral dopaminergic receptors B. It does not activate adrenergic β receptors C. It causes pronounced tachycardia D. It has good blood-brain barrier penetrability

Last Answer : A. It does not activate peripheral dopaminergic receptors

Ranitidine differs from cimetidine in the following respect: A. It is less potent B. It is shorter acting C. It does not have antiandrogenic action D. It produces more CNS side effect

Description : Ranitidine differs from cimetidine in the following respect: A. It is less potent B. It is shorter acting C. It does not have antiandrogenic action D. It produces more CNS side effect

Last Answer : C. It does not have antiandrogenic action

Pyridostigmine differs from neostigmine in that: A. It is more potent orally B. It is longer acting C. It produces less muscarinic side effects D. It does not have any direct action on NM receptors

Description : Pyridostigmine differs from neostigmine in that: A. It is more potent orally B. It is longer acting C. It produces less muscarinic side effects D. It does not have any direct action on NM receptors

Last Answer : B. It is longer acting

Pyridostigmine differs from neostigmine in that: A. It is more potent orally B. It is longer acting C. It produces less muscarinic side effects D. It does not have any direct action on NM receptors

Description : Pyridostigmine differs from neostigmine in that: A. It is more potent orally B. It is longer acting C. It produces less muscarinic side effects D. It does not have any direct action on NM receptors

Last Answer : B. It is longer acting

Methyldopa differs from clonidine in the following respect: A. It is less likely to cause rebound hypertension on sudden discontinuation B. It does not reduce plasma renin activity C. It has a central as well as peripheral site of antihypertensive action D. It does not produce central side effect

Description : Methyldopa differs from clonidine in the following respect: A. It is less likely to cause rebound hypertension on sudden discontinuation B. It does not reduce plasma renin activity C. It has a central as well as peripheral site of antihypertensive action D. It does not produce central side effect

Last Answer : A. It is less likely to cause rebound hypertension on sudden discontinuation

Tolerance to the antiparkinsonian action develops most rapidly in the case of: A. Levodopa B. Levodopa + carbidopa C. Amantadine D. Bromocriptine

Description : Tolerance to the antiparkinsonian action develops most rapidly in the case of: A. Levodopa B. Levodopa + carbidopa C. Amantadine D. Bromocriptine

Last Answer : C. Amantadine

Olanzapine has the following features except: A. It is an antipsychotic drug with weak D2 receptor blocking action B. It has potent 5-HT2 blocking and antimuscarinic actions C. It lowers seizure threshold D. It produces prominent extrapyramidal side effects

Description : Olanzapine has the following features except: A. It is an antipsychotic drug with weak D2 receptor blocking action B. It has potent 5-HT2 blocking and antimuscarinic actions C. It lowers seizure threshold D. It produces prominent extrapyramidal side effects

Last Answer : D. It produces prominent extrapyramidal side effect

The following is true of selegiline: A. It does not exert antiparkinsonian action unless combined with levodopa B. It overcomes the ‘on-off ’ effect in levodopa treated advanced parkinsonian patients C. It retards the progression of Parkinson's disease D. At doses used in parkinsonism it does not interfere with peripheral metabolism of dietary amines

Description : The following is true of selegiline: A. It does not exert antiparkinsonian action unless combined with levodopa B. It overcomes the on-off ' effect in levodopa treated advanced parkinsonian ... D. At doses used in parkinsonism it does not interfere with peripheral metabolism of dietary amines

Last Answer : . At doses used in parkinsonism it does not interfere with peripheral metabolism of dietary amines

The following drug is added to levodopa therapy of parkinsonism to attenuate ‘wearing off’ effect: A. Selegiline B. Trihexiphenidyl C. Amantadine D. Any of the abov

Description : The following drug is added to levodopa therapy of parkinsonism to attenuate ‘wearing off’ effect: A. Selegiline B. Trihexiphenidyl C. Amantadine D. Any of the abov

Last Answer : A. Selegiline

Use of carbidopa along with levodopa in the treatment of parkinsonism: A. Inhibits development of involuntary movements B. Minimises ‘on-off ’ effect’ C. Inhibits occurrence of behavioral abnormalities D. Accentuates nausea and vomiting

Description : Use of carbidopa along with levodopa in the treatment of parkinsonism: A. Inhibits development of involuntary movements B. Minimises ‘on-off ’ effect’ C. Inhibits occurrence of behavioral abnormalities D. Accentuates nausea and vomiting

Last Answer : B. Minimises ‘on-off ’ effect

The drug which abolishes the therapeutic effect of levodopa in parkinsonism, but not that of levodopacarbidopa combination is: A. Metoclopramide B. Pyridoxine C. Chlorpromazine D. Isoniazid

Description : The drug which abolishes the therapeutic effect of levodopa in parkinsonism, but not that of levodopacarbidopa combination is: A. Metoclopramide B. Pyridoxine C. Chlorpromazine D. Isoniazid

Last Answer : B. Pyridoxine

The following is true of bupropion except: A. It inhibits dopamine reuptake along with inhibiting noradrenaline reuptake B. It produces sedation as a side effect C. It is being used as an aid for smoking cessation D. It is likely to produce seizures in overdose

Description : The following is true of bupropion except: A. It inhibits dopamine reuptake along with inhibiting noradrenaline reuptake B. It produces sedation as a side effect C. It is being used as an aid for smoking cessation D. It is likely to produce seizures in overdose

Last Answer : B. It produces sedation as a side effect

The antiparkinsonian drug which acts by inhibiting the degradation of dopamine in the brain is: A. Carbidopa B. Amantadine C. Selegiline D. Bromocriptine

Description : The antiparkinsonian drug which acts by inhibiting the degradation of dopamine in the brain is: A. Carbidopa B. Amantadine C. Selegiline D. Bromocriptine

Last Answer : C. Selegiline

Choose the correct statement about ondansetron: A. It is a dopamine D2 receptor antagonist B. It suppresses postoperative nausea and vomiting C. It is the most effective antiemetic for motion sickness D. It is not effective by oral route

Description : Choose the correct statement about ondansetron: A. It is a dopamine D2 receptor antagonist B. It suppresses postoperative nausea and vomiting C. It is the most effective antiemetic for motion sickness D. It is not effective by oral route

Last Answer : B. It suppresses postoperative nausea and vomitin

Enalapril differs from captopril in that: A. It blocks angiotensin II receptors B. It does not produce cough as a side effect C. It is less liable to cause abrupt first dose hypotension D. It has a shorter duration of action

Description : Enalapril differs from captopril in that: A. It blocks angiotensin II receptors B. It does not produce cough as a side effect C. It is less liable to cause abrupt first dose hypotension D. It has a shorter duration of action

Last Answer : C. It is less liable to cause abrupt first dose hypotension

Choose the correct statement about lamotrigine: A. It is a dopaminergic agonist used in parkinsonism B. It acts by blocking NMDA-type of glutamate receptors C. It is a broad spectrum antiepileptic drug D. It suppresses tonic-clonic seizures, but worsens absence seizures

Description : Choose the correct statement about lamotrigine: A. It is a dopaminergic agonist used in parkinsonism B. It acts by blocking NMDA-type of glutamate receptors C. It is a broad spectrum antiepileptic drug D. It suppresses tonic-clonic seizures, but worsens absence seizures

Last Answer : C. It is a broad spectrum antiepileptic drug

The following antipsychotic drug has weak dopamine D2 but additional 5-HT2 blocking activity and benefits both positive and negative symptoms of schizophrenia: A. Loxapine B. Clozapine C. Pimozide D. Penfluridol

Description : The following antipsychotic drug has weak dopamine D2 but additional 5-HT2 blocking activity and benefits both positive and negative symptoms of schizophrenia: A. Loxapine B. Clozapine C. Pimozide D. Penfluridol

Last Answer : B. Clozapin

As per WHO guidelines, treatment of failure or relapse (category II) patients of smear positive pulmonary tuberculosis differs from that of new cases in the following respect(s): A. All 5 first line antitubercular drugs are given in the initial intensive phase B. Duration of intensive phase is increased to 5 months C. Three drugs (HRE) are given in the continuation phase instead of two (HR) D. Both 'A' and 'C'

Description : As per WHO guidelines, treatment of failure or relapse (category II) patients of smear positive pulmonary tuberculosis differs from that of new cases in the following respect(s): A. All 5 first line antitubercular drugs ... are given in the continuation phase instead of two (HR) D. Both 'A' and 'C'

Last Answer : D. Both 'A' and 'C'

Iron sorbitol-citric acid differs from iron dextran in that: A. It cannot be injected i.v. B. It is not excreted in urine C. It is not bound to transferrin in plasma D. It produces fewer side effects

Description : Iron sorbitol-citric acid differs from iron dextran in that: A. It cannot be injected i.v. B. It is not excreted in urine C. It is not bound to transferrin in plasma D. It produces fewer side effects

Last Answer : A. It cannot be injected i.v

Dopaminergic D1 and D2 as well as adrenergic α and β1, but not β2 receptors are activated by: A. Dopamine B. Dobutamine C. Methoxamine D. Phenylephrine

Description : Dopaminergic D1 and D2 as well as adrenergic α and β1, but not β2 receptors are activated by: A. Dopamine B. Dobutamine C. Methoxamine D. Phenylephrine

Last Answer : A. Dopamine

Dopaminergic D1 and D2 as well as adrenergic α and β 1, but not β 2 receptors are activated by: A. Dopamine B. Dobutamine C. Methoxamine D. Phenylephrine

Description : Dopaminergic D1 and D2 as well as adrenergic α and β 1, but not β 2 receptors are activated by: A. Dopamine B. Dobutamine C. Methoxamine D. Phenylephrine

Last Answer : A. Dopamine

The most important receptor involved in cytotoxic drug induced vomiting is: A. Histamine H1 receptor B. Serotonin 5-HT3 receptor C. Dopamine D2 receptor D. Opioid μ receptor

Description : The most important receptor involved in cytotoxic drug induced vomiting is: A. Histamine H1 receptor B. Serotonin 5-HT3 receptor C. Dopamine D2 receptor D. Opioid μ receptor

Last Answer : B. Serotonin

Oxethazaine is used for anaesthetizing gastric mucosa because: A. It is not absorbed from the gastrointestinal tract B. It remains largely unionized in acidic medium C. It is highly ionized in acidic medium D. It produces no systemic effects even at high doses

Description : Oxethazaine is used for anaesthetizing gastric mucosa because: A. It is not absorbed from the gastrointestinal tract B. It remains largely unionized in acidic medium C. It is highly ionized in acidic medium D. It produces no systemic effects even at high doses

Last Answer : B. It remains largely unionized in acidic medium

The distinctive features of fluoxetine compared to the typical tricyclic antidepressants include the following except: A. It is less likely to produce cardiac arrhythmias in overdose B. It infrequently produces sedative and anticholinergic side effects C. It can elevate mood of apparently nondepressed patients suffering from chronic somatic illness D. It does not block neuronal uptake of biogenic amines

Description : The distinctive features of fluoxetine compared to the typical tricyclic antidepressants include the following except: A. It is less likely to produce cardiac arrhythmias in overdose B. It infrequently ... suffering from chronic somatic illness D. It does not block neuronal uptake of biogenic amines

Last Answer : D. It does not block neuronal uptake of biogenic amines

Vincristine differs from vinblastine in the following respect(s): A. Its prominent adverse effect is neuropathy B. It frequently produces alopecia C. It does not significantly depress bone marrow D. All of the above

Description : Vincristine differs from vinblastine in the following respect(s): A. Its prominent adverse effect is neuropathy B. It frequently produces alopecia C. It does not significantly depress bone marrow D. All of the above

Last Answer : D. All of the above

Fluphenazine differs from chlorpromazine in the following respects except: A. It has higher antipsychotic efficacy B. It is less sedative C. It is less likely to precipitate seizures in epileptics D. It causes more prominent extrapyramidal side effect

Description : Fluphenazine differs from chlorpromazine in the following respects except: A. It has higher antipsychotic efficacy B. It is less sedative C. It is less likely to precipitate seizures in epileptics D. It causes more prominent extrapyramidal side effect

Last Answer : A. It has higher antipsychotic efficacy

Activation of the following type of receptors present on myenteric neurones by metoclopramide is primarily responsible for enhanced acetylcholine release improving gastric motility: A. Muscarinic M1 B. Serotonergic 5-HT3 C. Serotonergic 5-HT4 D. Dopaminergic D2

Description : Activation of the following type of receptors present on myenteric neurones by metoclopramide is primarily responsible for enhanced acetylcholine release improving gastric motility: A. Muscarinic M1 B. Serotonergic 5-HT3 C. Serotonergic 5-HT4 D. Dopaminergic D2

Last Answer : C. Serotonergic 5-HT4

The newer lipid formulations of amphotericin B differ from the conventional formulation in the following respects except: A. They are more efficacious B. They produce milder acute reaction C. They are less nephrotoxic D. They produce milder anaemia

Description : The newer lipid formulations of amphotericin B differ from the conventional formulation in the following respects except: A. They are more efficacious B. They produce milder acute reaction C. They are less nephrotoxic D. They produce milder anaemia

Last Answer : A. They are more efficacious

Methyldopa lowers BP by: A. Inhibiting dopa decarboxylase in adrenergic nerve endings B. Generating α-methyl noradrenaline in brain which reduces sympathetic tone C. Generating α-methyl noradrenaline which acts as a false transmitter in peripheral adrenergic nerve endings D. Activating vascular dopamine receptors

Description : Methyldopa lowers BP by: A. Inhibiting dopa decarboxylase in adrenergic nerve endings B. Generating α-methyl noradrenaline in brain which reduces sympathetic tone C. Generating α-methyl ... as a false transmitter in peripheral adrenergic nerve endings D. Activating vascular dopamine receptors

Last Answer : B. Generating α-methyl noradrenaline in brain which reduces sympathetic tone

Mesalazine (coated 5-amino salicylic acid) differs from sulfasalazine in that: A. It is more effective in ulcerative colitis B. It produces less adverse effect C. It has no therapeutic effect in rheumatoid arthritis D. Both ‘B’ and ‘C’ are correc

Description : Mesalazine (coated 5-amino salicylic acid) differs from sulfasalazine in that: A. It is more effective in ulcerative colitis B. It produces less adverse effect C. It has no therapeutic effect in rheumatoid arthritis D. Both ‘B’ and ‘C’ are correc

Last Answer : D. Both ‘B’ and ‘C’ are correct

Piperacillin differs from carbenicillin in the following respect(s): A. It is more active against Pseudomonas aeruginosa B. It is active against Klebsiella as well C. It is acid resistant D. Both ‘A’ and ‘B’ are correct

Description : Piperacillin differs from carbenicillin in the following respect(s): A. It is more active against Pseudomonas aeruginosa B. It is active against Klebsiella as well C. It is acid resistant D. Both ‘A’ and ‘B’ are correct

Last Answer : D. Both ‘A’ and ‘B’ are correct